1
|
Nadhim AN, wong J, Gupta D, Suhan L, Siegel M, Bhat S, strauss S, Fourcard F, Pandya V. 1149 A Pilot Quality Improvement (QI) Study To Assess Whether Bilevel Positive Airway Pressure (bipap) Support In Acute Ischemic Stroke Patients With Sleep Disordered Breathing, Can Improve Neurological Recovery During Acute Stroke Care. Sleep 2020. [DOI: 10.1093/sleep/zsaa056.1143] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
Obstructive sleep apnea (OSA) has been associated with adverse outcomes in patients with stroke. While data is limited, it suggests that treatment of OSA may improve neurological recovery. With this quality improvement (QI) project, we aim to develop an interprofessional-team workflow process for screening and correction of OSA in acute ischemic stroke, with the goal to improve outcomes of neurological recovery.
Methods
This is an ongoing study to screen all eligible patients admitted to JFK Medical Center stroke unit, with MRI-proven Supratentorial acute ischemic stroke. The patients are screened using an overnight Pulse Oximetry test. A 3% oxygen desaturation index (ODI) of ≥10/hr or 4% ODI of ≥ 5/hr is considered at high risk for OSA. Such Patients will receive nocturnal Auto-adjusting BIPAP therapy during their acute care stay, for up to 5 days, for at least 4 hours per night. Eligible Patients who refused BiPAP therapy or were non-compliant will be considered as a controls. Baseline NIH stroke scale (NIHSS), and bilateral MCA mean flow velocity (MFV) in the morning, by transcranial doppler (TCD) will be assessed at baseline for cases and controls, and after BiPAP therapy, for the case group. The two groups of patients will also be compared in terms of Modified Rankin Scale at time of discharge and at phone follow-up after 6 weeks.
Results
Between Oct 17th, 2019 to current, 15 patients were admitted to the stroke unit with MRI confirmed stroke. Ages ranged from 34 - 88 years (average age 66.5 years). 8 patients (60%) were female. Of those, 6 patients consented to being screened for OSA. Of these, 1 had 4%ODI >5/hr, and therefore received treatment with BIPAP. However, compliance was < 4 hrs on 2 consecutive nights.
Conclusion
This is ongoing QI project and results will be available after few more months of continued recruitment.
Support
Auto-adjusting BIPAP machines were provided by RESMED.
Collapse
Affiliation(s)
| | - J wong
- JFK Neuroscience institute, Edison, NJ
| | - D Gupta
- JFK Neuroscience institute, Edison, NJ
| | - L Suhan
- JFK Neuroscience institute, Edison, NJ
| | - M Siegel
- JFK Neuroscience institute, Edison, NJ
| | - S Bhat
- JFK Neuroscience institute, Edison, NJ
| | - S strauss
- JFK Neuroscience institute, Edison, NJ
| | - F Fourcard
- JFK Neuroscience institute, perth amboy, NJ
| | - V Pandya
- JFK Neuroscience institute, perth amboy, NJ
| |
Collapse
|
2
|
Jain MR, Joharapurkar AA, Pandya V, Patel V, Joshi J, Kshirsagar S, Patel K, Patel PR, Desai RC. Pharmacological Characterization of ZYAN1, a Novel Prolyl Hydroxylase Inhibitor for the Treatment of Anemia. Drug Res (Stuttg) 2015; 66:107-12. [PMID: 26367279 DOI: 10.1055/s-0035-1554630] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
Prolyl hydroxylase (PHD) inhibitors stabilize hypoxia inducible factor (HIF), and exert antianemic effect by potentiating erythropoietin (EPO) expression and down-regulation of hepcidin. ZYAN1 is a novel PHD inhibitor under clinical development for the treatment of anemia. The pharmacodynamic effects of acute and chronic dosing of ZYAN1 were assessed in normal and 5/6 nephrectomized Wistar rats. The effect of ZYAN1 was also investigated in cisplatin-induced anemia using C57 mice. Acute treatment with ZYAN1 increased circulating EPO levels (10.3 ± 3.7 and 40.0 ± 8.5 fold rise at 15 and 30 mg/kg, respectively), reticulocyte count (4.2 ± 0.5 and 6.0 ± 0.2 fold rise at 15 and 30 mg/kg, respectively) and stabilized HIF (28% increase at 45 mg/kg) in normal rats. Nephrectomized rats showed similar dose-related pharmacodynamic effects. In a 28-day study in nephrectomized rats, ZYAN1 administered every alternate day, caused increase in hemoglobin (1.9 ± 0.3 and 2.5 ± 0.4 g/dL) and RBC count (10.7 ± 4.0 and 14.0 ± 4.1%) at 15 and 30 mg/kg respectively. In cisplatin-treated mice also an increase in hemoglobin (3.4 ± 0.2 and 5.9 ± 0.2 g/dL) and RBC count (22.5 ± 2.2 and 37.3 ± 1.7%) at 15 and 30 mg/kg respectively was observed. ZYAN1's effects on hemoglobin and RBC count were distinct from darbepoietin. ZYAN1 demonstrated hematinic potential by combined effects on EPO release and efficient iron utilization. The efficacy of ZYAN1 in disease models of different etiologies suggests that it will be useful in treating wide spectrum of anemia patients.
Collapse
Affiliation(s)
- M R Jain
- Department of Pharmacology & Toxicology, Zydus Research Centre, Cadila Healthcare Limited, Ahmedabad, India
| | - A A Joharapurkar
- Department of Pharmacology & Toxicology, Zydus Research Centre, Cadila Healthcare Limited, Ahmedabad, India
| | - V Pandya
- Department of Medicinal Chemistry, Zydus Research Centre, Cadila Healthcare Limited, Ahmedabad, India
| | - V Patel
- Department of Pharmacology & Toxicology, Zydus Research Centre, Cadila Healthcare Limited, Ahmedabad, India
| | - J Joshi
- Department of Medicinal Chemistry, Zydus Research Centre, Cadila Healthcare Limited, Ahmedabad, India
| | - S Kshirsagar
- Department of Pharmacology & Toxicology, Zydus Research Centre, Cadila Healthcare Limited, Ahmedabad, India
| | - K Patel
- Department of Pharmacology & Toxicology, Zydus Research Centre, Cadila Healthcare Limited, Ahmedabad, India
| | - P R Patel
- Department of Pharmacology & Toxicology, Zydus Research Centre, Cadila Healthcare Limited, Ahmedabad, India
| | - R C Desai
- Department of Medicinal Chemistry, Zydus Research Centre, Cadila Healthcare Limited, Ahmedabad, India
| |
Collapse
|